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Abstract
The mechanisms by which PGC-1a gene expression is controlled in skeletal muscle remains largely undefined. Thus, we
sought to investigate the transcriptional regulation of PGC-1a using AICAR, an activator of AMPK, that is known to increase
PGC-1a expression. A 2.2 kb fragment of the human PGC-1a promoter was cloned and sequence analysis revealed that this
TATA-less sequence houses putative consensus sites including a GC-box, a CRE, several IRSs, a SRE, binding sites for GATA,
MEF2, p 53, NF-kB, and EBox binding proteins. AMPK activation for 24 hours increased PGC-1a promoter activity with
concomitant increases in mRNA expression. The effect of AICAR on transcriptional activation was mediated by an
overlapping GATA/EBox binding site at 2495 within the PGC-1a promoter based on gel shift analyses that revealed
increases in GATA/EBox DNA binding. Mutation of the EBox within the GATA/EBox binding site in the promoter reduced
basal promoter activity and completely abolished the AICAR effect. Supershift analyses identified USF-1 as a DNA binding
transcription factor potentially involved in regulating PGC-1a promoter activity, which was confirmed in vivo by ChIP.
Overexpression of either GATA-4 or USF-1 alone increased the p851 PGC-1a promoter activity by 1.7- and 2.0-fold
respectively, while co-expression of GATA-4 and USF-1 led to an additive increase in PGC-1a promoter activity. The USF-1-
mediated increase in PGC-1a promoter activation led to similar increases at the mRNA level. Our data identify a novel AMPK-
mediated regulatory pathway that regulates PGC-1a gene expression. This could represent a potential therapeutic target to
control PGC-1a expression in skeletal muscle.
Citation: Irrcher I, Ljubicic V, Kirwan AF, Hood DA (2008) AMP-Activated Protein Kinase-Regulated Activation of the PGC-1a Promoter in Skeletal Muscle
Cells. PLoS ONE 3(10): e3614. doi:10.1371/journal.pone.0003614
Editor: Alejandro Lucia, Universidad Europea de Madrid, Spain
Received May 16, 2008; Accepted September 30, 2008; Published October 31, 2008
Copyright:  2008 Irrcher et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was funded by the Canadian Institutes of Health Research, and the Natural Science and Engineering Research Council of Canada (NSERC;
DAH). II and VL were recipients of scholarships from NSERC. VL was the recipient of a scholarship from the Heart and Stroke Foundation of Canada. DAH is the
holder of a Canada Research Chair in Cell Physiology. The funding sources had no role in the design and conduct of the study, in the collection, analysis,a n d
interpretation of data, and in the preparation, review, or approval of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dhood@yorku.ca
Introduction
Skeletal muscle exhibits remarkable plasticity in response
changing energy demands. For example, repeated bouts of exercise
in the form of endurance exercise training of an appropriate time,
duration and intensity can induce mitochondrial phenotype and
content changes within muscle cells, a process termed mitochondrial
biogenesis. This adaptation is associated with numerous clinical and
health related benefits including improvements in oxidative capacity
[1], exercise tolerance [2], the alleviation of symptoms associated
with physical inactivity-related diseases such as insulin resistance [3],
as well as the possible attenuation of the decline in oxidative capacity
associated with aging [4]. Mitochondrial biogenesis is controlled via
the actions of numerous transcription factors and transcriptional co-
activators. This serves to coordinate the nuclear and mitochondrial
genomes, and ultimately plays an important role in regulating the
stoichiometric production and assembly of the proteins involved in
organelle synthesis [5].
Recently, the transcriptional co-activator PPARc-coactivator-1
protein a (PGC-1a) has been proposed to play a central role in
regulating mitochondrial content within cells [6,7]. PGC-1a is
induced by mitochondrial biogenesis-inducing stimuli such as
thyroid hormone treatment, as well as contractile activity in vivo
and in vitro in skeletal muscle [8,9,10]. Moreover, low levels of
PGC-1a expression in muscle have been associated with defects in
energy metabolism, in addition to reduced mitochondrial content
and function [11,12]. The importance of PGC-1a in regulating
mitochondrial content and function suggests that further investi-
gation into the regulation of PGC-1a gene expression is warranted
particularly under conditions in which mitochondrial biogenesis is
induced. In recent years, several signaling kinases have been
implicated in mediating the transcriptional activation of the PGC-
1a promoter activity and mRNA expression in response to various
stimuli [13–17] suggesting that PGC-1a gene expression is
controlled, in part, at a transcriptional level. The signaling events
associated with the induction of mitochondrial biogenesis and
increases in PGC-1a gene expression within skeletal muscle
remain largely undefined.
In skeletal muscle, numerous signaling kinases involved in
initiating mitochondrial biogenesis have been described including
the activation of AMP-kinase (AMPK). A decrease in the ratio of
ATP/AMP within muscle cells activates AMPK [18,19]. Phar-
macological activation of AMPK using 5-aminoimidazole-4-
carboxamide-1-b-D-ribofuranoside (AICAR) stimulates mitochon-
drial biogenesis, and this is likely to occur through the induction of
PGC-1a [9,18]. AMPK is also activated by exercise in rodents
[20], humans [21,22] and following electrical stimulation of
skeletal muscle [9,23], stimuli which are known to induce
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3614mitochondrial biogenesis. Since AMPK is likely a key signaling
molecule in the pathway leading to mitochondrial biogenesis in
skeletal muscle, we sought to investigate the potential role of
AMPK in regulating PGC-1a expression via transcriptional
activation of its promoter. Here we report the characterization
of the human PGC-1a promoter in skeletal muscle cells, and
examine its regulation following activation of AMPK via AICAR.
Furthermore, we identify potential AMPK transcription factor
targets that mediate increases in PGC-1a transcription in muscle.
Results
Characterization of the proximal 2 kb human PGC-1a
promoter
The mechanism(s) regulating PGC-1a transcription were first
investigated by cloning the proximal 2 kb sequence of the human
PGC-1a promoter. This sequence contains +28 to 22190
nucleotides relative to the first transcriptional start site (GenBank
Accession No. BD103728; [24]. Inspection of this sequence for the
presence of consensus transcription factor binding sites was
performed by high stringency searches using PATCH (Pattern
search for transcription factor binding sites) and TRANSFAC 6.0.
The odds of identifying false positives were minimized by
excluding non-canonical sequences, or sequences that contained
nucleotide mismatches. The putative DNA binding sites that were
found within the hPGC-1a promoter are identified in Fig. 1.
Although the promoter does not appear to contain a TATA box,
our search identified a putative GC Box within the first intron that
has been shown to bind Sp1 [25]. This finding is also in line with
those of Esterbauer et al [24]. In addition to the putative Sp1 site,
there is one consensus cAMP Response Element (CRE) at position
2133, three insulin response sequences (IRS) at 2354, 2589, and
2979, and one Muscle Enhancer Factor-2 (MEF2) site at 21335.
These sequences have recently been shown to bind the cAMP
Response Element Binding protein (CREB) and a CREB-related
family member, Activating Transcription Factor 2 (ATF2), the
forkhead transcription factor (FKHR) and MEF2, respectively
[15,16,26]. Our search also identified three GATA sequences at
2493, 21605, and 21961, as well as a consensus sequence
representing the serum response element (SRE) at 2705 upstream
from the transcriptional start site. Putative binding sites for p53 at
21237 and NF-kB at 21575, as well as multiple EBoxes at 223,
2362, 2495, 2785, 21083, 21190, 21927, 21995 and 22185
were also found within the PGC-1a promoter.
Effect of AICAR on AMPK activation and PGC-1a
transcription
AMPK activation via AICAR treatment has previously been
shown to upregulate PGC-1a mRNA and protein expression in
skeletal muscle [9,27–29]. Thus, we used AICAR to investigate the
AMPK-mediated transcriptional control of PGC-1a in C2C12
cells. Following 24 hours of treatment with AICAR, AMPK
activation via phosphorylation on Thr172 was increased by 4.5-
fold (p,0.05; Fig. 2A). This occurred concomitantly with a 2.2-
fold increase (p,0.05) in PGC-1a mRNA expression (Fig. 2B).
Next, a series of 59-deletions of the 2 kb PGC-1a promoter were
generated and transfected into cells to determine whether this was
related to increased transcriptional activity. The responsiveness of
the promoter-luciferase reporter constructs to AMPK activation
was assessed after 24 hours of treatment with 1 mM AICAR. A
two-way ANOVA was performed and a significant main effect of
promoter length was found. Post-hoc tests revealed significant 3.5-
and 1.8-fold increases (p,0.05) in the p 851 and p191 promoters
respectively, as well as a 2.2-fold decrease (p,0.05) in the p1164
promoter (Fig. 2C). To evaluate whether the 2823 to 2473
AICAR-responsive region (ARR) is sufficient to activate a minimal
promoter, a construct containing this region was cloned upstream
of a minimal promoter in the pGL4.23 reporter vector. Two-way
ANOVA revealed a significant interaction (p,0.05) between the
ARR and the effect of AICAR (Fig. 2D). Post-hoc tests indicated a
significant 3.1- fold increase (p,0.05) in basal promoter activity.
This activity of the AICAR-responsive region was further
increased 2-fold (p,0.05) in the presence of AICAR.
Effect of AMPK activation on DNA binding and protein
expression
The responsiveness of the PGC-1a promoter to AICAR
suggested that AMPK activation could mediate at least part of
the increase PGC-1a mRNA expression via transcriptional
activation. Since the largest portion of the activation effect
occurred between 2474 and 2823 bp of the promoter (Fig. 2C),
we evaluated the DNA binding activities of proteins bound to the
putative consensus sequences within this region using gel shift
analyses. The binding sites for the transcription factors found
within this AICAR-responsive region of the promoter are shown in
Fig. 1. They include an overlapping EBox/GATA sequence, an
IRS sequence that binds FKHR [16], as well as an SRE and an
EBox. AICAR treatment had no effect on the binding of proteins
bound to the EBox, SRE, or the IRS sequences (Fig. 3A).
However, AICAR treatment led to an ,2.0-fold increase (p,0.05;
Fig. 3B) in GATA/Ebox DNA binding. A number of possible
candidate proteins exist which could bind to this overlapping
sequence, a GATA isoform (i.e. GATA-4), c-myc, Upstream
Stimulatory Factor (USF-1) or MyoD [30–32]. Analyses using
specific antibodies against GATA-4, c-myc and MyoD did not
reveal a supershift in the GATA/EBox-DNA complex (Fig. 3B
and C). However, a strong supershifted complex was apparent in
the presence of the USF-1 Ab (Fig. 3C), suggesting that USF-1 is a
protein bound to the EBox within this sequence. The physiological
relevance of this finding in vivo was evaluated with the use of ChIP
analysis in which we found USF-1 bound to the PGC-1a promoter
in non-stimulated conditions (Fig. 3D, lane 3). Following 24 hours
of AICAR treatment, the amount of USF-1 bound to the PGC-1a
promoter in vivo was increased by 2.3-fold (Fig. 3D, lane 5),
consistent with the gel shift analysis above.
We then tested whether AMPK activation targets the EBox, the
GATA sequence, or both sequences to transcriptionally activate
the PGC-1a promoter by generating mutations within the EBox/
GATA oligonucleotides to abolish either Ebox or GATA binding
separately (Fig. 4A). Mutation of the GATA sequence shifted the
DNA binding complex to a lower molecular weight, consistent
with the absence of GATA-4 (Fig. 4B, lane 4–5 from the left).
Although USF-1 was still present in the complex, the AICAR
effect on protein-DNA binding was reduced (lane 7). However,
when the EBox was mutated, USF-1 binding was prevented (lanes
10, 11), and the AICAR effect was abolished (lane 13). These data
suggest that transcription factor binding to the EBox sequence is
more important to mediate the effect of AMPK activation, but also
suggest the fact that GATA could modulate the AMPK effect on
DNA binding in regulating the activity of the promoter. This is
suggested by the results showing that GATA-4 overexpression
alone increased the transcriptional activity of the PGC-1a
promoter (see below). Although the identity of the specific GATA
isoform bound to the GATA sequence remains unresolved,
GATA-4 is expressed in striated muscle [33], which suggests the
possibility that the GATA-4 isoform is the likely candidate to
mediate transcription of the PGC-1a promoter at this site.
PGC-1a Transcriptional Control
PLoS ONE | www.plosone.org 2 October 2008 | Volume 3 | Issue 10 | e3614Figure 1. The human PGC-1a promoter. The nucleotide sequence +28 to 22190 corresponding to the proximal 2-kb hPGC-1a promoter is shown.
The arrows indicate the transcription start sites, which have been previously described [14]. Putative binding sites for transcription factors are either
underlined or overlined. Also included are binding sites for transcription factors that have previously been characterized [12;13;19]. Numbers enclosed in
circles represent the 59- deletions of the PGC-1a promoter reporter constructs A p2 2 1 5 ,B p 1164, C p8 5 1 ,D p501, E p 191 as shown in Fig. 2.
doi:10.1371/journal.pone.0003614.g001
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PLoS ONE | www.plosone.org 3 October 2008 | Volume 3 | Issue 10 | e3614The importance of the EBox as the primary mediator of the
AICAR effect on PGC-1a promoter activity was further evaluated by
generatingareporterconstruct inwhichmutationswereincorporated
into the Ebox sequence of the overlapping GATA/EBox sequence
within the p851 promoter length. This mutation effectively prevented
EBox protein/DNA binding. As shown in Fig. 4C, the typical effect
ofAICARonthep 851promoter length wasabolished by amutation
of the EBox within the overlapping GATA/EBox. In addition, basal
PGC-1a promoter activity was also reduced. These data, together
with the DNA binding assays, suggest that USF-1 regulates both basal
and AICAR-induced PGC-1a promoter activity.
To evaluate whether the increase in DNA binding observed
in the presence of AICAR was the result of increased protein
expression, we measured USF-1 and GATA-4 protein by
Figure 2. AMPK activation induces PGC-1a mRNA expression and transcriptionally activates the PGC-1a promoter. C2C12 cells were
treated with either AICAR (1 mM) or Vehicle for 24 hrs. A. Representative Western Blot probed with a Phospho-AMPKa (Thr172), stripped and then re-
probed with total AMPKa for loading control (upper panel). Summary of repeated experiments of the effect of AICAR on AMPK activation is shown
(lower panel; n=4). B. upper panel, EtBr-stained DNA gel of PGC-1a amplified by PCR from vehicle- and AICAR-treated cells. GAPDH was also
amplified by PCR and used to verify equal loading. Lower panel: A summary of repeated experiments of the effects of AICAR on PGC-1a mRNA
expression (n=3). C. AICAR-induced transcriptional regulation of the PGC-1a promoter. Relative luciferase activity of the PGC-1a promoter constructs
in vehicle- or AICAR-treated cells is shown (n=4–6). D. The AICAR-responsive region (ARR) from 2473 to 2821 was cloned into the pGL4.23 minimal
promoter vector and AICAR-induced transcriptional regulation of this region was assessed (n=3). For all data, values are means6S.E.M, *, p,0.05
versus Vehicle-treated control; 1,p ,005 versus pGL4.23.
doi:10.1371/journal.pone.0003614.g002
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on either GATA-4 or USF-1 protein levels. Thus, the increase
in DNA binding is likely attributed to AICAR-mediated post-
translational modifications (i.e. phosphorylation) that may either
directly or indirectly affect the transcriptional activity of GATA-
4 or USF-1. There are numerous possibilities to explain the
manner in which these modifications could occur. These include
the direct AMPK-mediated phosphorylation of either GATA-4
or USF-1. Alternatively, the effect could be indirect and occur
at multiple steps downstream of AMPK activation. Since the
Figure 3. AMPK activation increases GATA/EBox DNA binding. A. Representative EMSAs of nuclear extracts from Vehicle2 (2AIC) and
AICAR2 (+AIC) treated cells that were incubated with radiolabeled oligonucleotides corresponding to the EBox, SRE and IRS sequences found within
the AICAR-responsive region of the PGC-1a promoter (as shown in Fig. 1). B. A representative EMSA (Left panel) and a summary of multiple
experiments (Right panel) showing the effect of AICAR (A) on GATA/EBox-DNA binding. Values are represented as means6S.E.M (n=8) relative to
vehicle-treated (V) cells. C. Representative EMSAs of nuclear extracts that were incubated with radiolabeled oligonucleotides corresponding to GATA/
EBox wt. Vehicle-treated cells were incubated with radiolabeled oligonucleotides corresponding to GATA/EBox wt as well as antibodies against
MyoD, USF-1 and c-Myc which are known to bind to the EBox sequence. FP: free probe, 256,5 0 6, 1006CO: 25-fold, 50-fold, 100-fold molar excess of
cold oligo, No Ab: No Antibody, SRF: SRF antibody, FKHR: Forkhead antibody, GATA-4: GATA-4 antibody, c-Myc: c-Myc Antibody, USF-1: USF-1
antibody. **The representative blot of IRS/DNA binding was made from parts of the same gel. D. Representative chromatin immunoprecipitation
from cells treated with or without 1 mM AICAR for 24 hours. Protein/DNA complexes were immunoprecipitated with USF-1 antibody, or with non-
specific IgG. Primers encompassing the region between 2473 and 2823 were used to analyze USF-1 binding to the PGC-1a promoter. The
representative blot on the left was made from parts of the same gel. At right is a graphical summary of repeated experiments. Values are
representative of means6S.E.M (n=6).
doi:10.1371/journal.pone.0003614.g003
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PLoS ONE | www.plosone.org 5 October 2008 | Volume 3 | Issue 10 | e3614cellular signals and regulatory pathways that influence PGC-1a
gene expression are not yet well understood, the elucidation of
the underlying molecular mechanisms regulating PGC-1a gene
transcription in response to AMPK activation are worthy of
future study.
Effect of GATA-4 and USF-1 overexpression on PGC-1a
transcription and mRNA expression
WesoughttoidentifywhetherGATA-4andUSF-1couldmediate
PGC-1a transcription independently. Thus, we overexpressed
GATA-4, USF-1 or the two in combination in muscle cells.
IncreasesinthelevelsofGATA-4orUSF-1proteinweredetectedby
Western Blotting in cells transfected with 4 mg of DNA (Fig. 5A).
USF-1 overexpression alone increased promoter activity by 1.7 fold
(p,0.001), in addition to producing an increase in PGC-1a mRNA
(Fig.5C).The enhancedeffectofUSF-1overexpressiononpromoter
activity was not observed when the p851mtEbox was transfected,
indicating that the USF-1 effect occurs via the Ebox element (data
not shown). GATA-4 overexpression led to a 2.0- fold increase in
promoter activity (p,0.05; Fig. 5B), but did not lead to increases in
PGC-1a mRNA. This latter result was expected, since the GATA
element found within the human promoter is not conserved in the
mouse. The combination of USF-1 and GATA-4 overexpression
produced a further significant increase in PGC-1a promoter activity
to 2.5-fold above the empty vector control. The magnitude of this
increase is suggestive of an additive effect of the two proteins on
PGC-1a transcription.
Discussion
PGC-1a regulates many important aspects of skeletal muscle
biology including the stimulation of mitochondrial biogenesis and
cellular respiration, muscle fiber type transitions, glucose metab-
olism as well as fatty acid oxidation [7,27,34,35]. Significant health
benefits can be derived from improvements in any of these factors
in healthy individuals, and also in aging, obese, and/or physically
inactive populations in which mitochondrial content or substrate
metabolism is compromised. Thus, research efforts dedicated to
the elucidation of the cellular signals and the regulatory pathways
that influence PGC-1a gene expression are warranted, particularly
under circumstances in which mitochondrial biogenesis is induced.
Several studies have established that endogenous PGC-1a gene
expression is increased following contractile activity and thyroid
hormone treatment in skeletal muscle [8–10,23,29,36–38]. In
addition, some of the cellular signals arising from muscle
contraction that could account for this induction have also been
recently identified. They include changes in intracellular Ca
2+,
and/or alterations in cellular energy status that activate AMPK
[9,18,39,40]. AMPK activation either during contractile activity,
or with the use of the AMP analogue AICAR, has been associated
with greater mitochondrial enzyme activities and PGC-1a
expression in a variety of different experimental models
[9,18,28,40]. However, the detailed molecular mechanisms, as
well as the direct effect of AMPK on PGC-1a gene transcription,
have not yet been established. Thus, we employed the pharma-
cologic activation of AMPK in order to more precisely define the
regulatory pathway which leads increased PGC-1a mRNA
expression in skeletal muscle.
We show here that the use of AICAR for 24 hours activates
AMPK and increases PGC-1a mRNA expression, a finding that is
similar to that observed by others using different experimental
models [27,37,40]. Since the underlying cause of this induction is
proposed to be linked to a transcriptional mechanism [13–17], we
cloned a proximal sequence of the PGC-1a promoter and
analyzed this fragment with stringent computer-assisted analyses
to identify candidate transcription factor binding sites that could
mediate the AICAR effect. This 2.2 kb sequence was found to
Figure 4. Mutations to either GATA or EBox elements alters
AICAR-induced increases in GATA/EBox DNA binding and
affects PGC-1a promoter activity. A. A schematic of the overlap-
ping EBox/GATA (GATA/EBoxwt) binding sites at 2495 and 2486 base
pairs within the PGC-1a promoter is shown. Mutations to the GATA/
EBoxwt oligonucleotide that were introduced by nucleotide exchange
to abolish GATA (GATAmt) or EBox (EBoxmt) binding are bolded. B.
Representative EMSAs of Vehicle- (2) and AICAR2 (+) treated nuclear
extracts incubated with GATAmt or EBoxmt radiolabeled probes in the
presence or absence of USF-1 Antibody. FP: free probe, 256 CO, and
50CO: 25-fold and 50-fold molar excess of cold oligonucleotide, No Ab:
No Antibody, USF-1: USF-1 antibody. C. Relative luciferase activity of the
PGC-1a promoter constructs in vehicle- or AICAR-treated cells is shown.
Values are means6S.E.M, * p,0.05 versus Vehicle-treated control
(n=3). D. Western blot analysis of GATA-4 and USF-1 protein expression
from total proteins extracted from vehicle2 (2) and AICAR (+)-treated
cells is shown. GAPDH expression was used as a loading control.
doi:10.1371/journal.pone.0003614.g004
PGC-1a Transcriptional Control
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typically found within the regulatory regions of muscle-specific
genes [6,41–45]. To our knowledge, this represents the first
extensive documentation and characterization of the human PGC-
1a promoter, other than the identification of the genomic
organization and chromosomal location of the pgc-1gene by
Esterbauer et al., [24]. Interestingly, none of the putative binding
sites that were identified by our analysis had been previously
identified as AMPK targets. Thus, we generated a series of 59-
deletion constructs to test the general responsiveness of the
promoter to AICAR and also to identify the regulatory regions
responsible for regulating PGC-1a transcription.
Our data show that both AICAR-positive and -negative regions
are present within the 2.2 kb sequence. This is highlighted by the
fact that not all PGC-1a promoter lengths were positively affected
by AICAR. This suggests that there are several putative binding
sites for transcription factors that confer a negative effect on PGC-
1a promoter activity. These data therefore establish that a
combinatorial interplay between positive and negative stimuli
ultimately act on the PGC-1a promoter to upregulate PGC-1a
mRNA expression. Since endogenous PGC-1a mRNA expression
was increased in response to AICAR, we sought to elucidate
mechanisms which could account for the effects of this AMP
analogue. The two AICAR-positive regions that were identified
Figure 5. Effect of GATA-4 and USF-1 overexpression on PGC-1a promoter activity and mRNA expression. A. Representative western
blots of protein extracts made from C2C12 cells transfected with either 2 or 4 mg of GATA-4 or USF-1 or an empty vector (EV) control. B. USF-1 and
GATA-4 were co-transfected with the pGL3 (EV; 500ng) or the p851 PGC-1a promoter reporter construct (500ng) along with the appropriate empty
vector controls. Relative luciferase activities were measured 48 hours after transfection and are plotted as the fold change above empty vector.
Values are means6SEM, (n=8); * p,0.05 versus p851-EV and #,p ,0.05 versus p851-USF-1 or p851-GATA-4. C. Cells were transfected with 4 mgo f
USF-1 or an empty vector (EV) control. EtBr-stained DNA gel of PGC-1a amplified by PCR from EV- and USF-1 transfected cells. s12rRNA was used to
verify equal loading. Data are representative of one experiment with conditions repeated in duplicate (AU=arbitrary units).
doi:10.1371/journal.pone.0003614.g005
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elements within the p 191 promoter as well as the binding sites
found at 2823 to 2473. However, two pieces of evidence suggest
that the latter region accounts for the majority of the responsive-
ness to AICAR. First, the AICAR-responsive region between
2823 and 2473 is sufficient to transcriptionally activate a
minimal promoter in response to AICAR. Second, gel shift
experiments and promoter assays using oligos, or using the 851
promoter length in which the EBox of the overlapping GATA/
EBox was mutated, completely abolished the AICAR effect. These
findings highlight an unexpected appreciation for the complexity
that underlies the regulation of PGC-1a promoter activity, given
the recent work by Akimoto et al., [14] in which they
demonstrated that the exercise-induced activation of PGC-1a
transcription in muscle relies exclusively on a distal MEF and a
proximal CRE sequence. Based on their findings, we anticipated
that AMPK activation by AICAR would elicit an increase in the
activity of the promoter fragment containing either the MEF2 site
(i.e. p 2218) and/or the CRE site (p 191), since AMPK is activated
both by exercise [20–22], as well as by electrically-evoked
contractions in C2C12 cells [9]. Thus, our experimental approach
to assess PGC-1a promoter regulation using a variety of deletion
constructs has allowed us to characterize additional regulatory
elements that were unidentifiable using only one promoter length.
Further characterization of the DNA sequences that lie upstream
of 2.2 kb are also likely to reveal additional regulatory regions, since
the relative effect of the AICAR response with respect to promoter
activation (3.5-fold) and mRNA expression (2.2-fold) in this study
were not of equal magnitude. For example, an important distal
MEF2 site, identified at 22901 bp inthe mouse promoter [15], may
be involved. In the human PGC-1a promoter, this MEF2 site is
found at position 23344, and may have a similar function in the
regulation of PG-1a expression. In addition, several alternative
explanations that may account for the differences in the responses to
AMPK activation, including alterations in mRNA stability and a
divergence in the mechanisms governing the regulation of the
endogenous versus the ectopically expressed promoter, were
considered. Our preliminary observations indicate that the
AICAR-mediated increase in PGC-1a mRNA expression is not
the result of enhanced mRNA stability (Irrcher and Hood,
unpublished observations). However, some of the differences in
response to AICAR may be explained in part by the protective effect
of histones surrounding the endogenous promoter. This argument is
supported by the recent report that the in vivo regulation of the PGC-
1a promoter by HDAC5 is a key mechanism influencing
endogenous PGC-1a expression in the heart [15].
We evaluated a role for GATA and Ebox binding proteins in the
direct regulation of PGC-1a promoter activity and mRNA
expression. Supershift analyses clearly identified USF-1 as a protein
bound to the overlapping GATA/EBox sequence, which was
confirmed in vivo using chromatin immunoprecipitation. Further-
more, overexpression of USF-1 increased PGC-1a promoter activity
and led to a similar induction in PGC-1a mRNA expression.
GATA-4 overexpression also increased PGC-1a promoter activity.
Because mutation of the GATA element failed to reduce DNA
binding in electromobility shift analyses (Fig. 4B), and because
mutation of the Ebox reduced the AICAR effect to that of control
values (Fig. 4C), we believe that PGC-1a expression is more likely to
be regulated by USF-1 rather than GATA-4 in response to AICAR.
Although the Ebox within the overlapping sequence mediates the
AICAR effect on PGC-1a promoter activation, the fact that AICAR
also induces the activation of the p191 reporter construct suggests
that the mRNA response may also rely on the cooperative actions
between USF-1, GATA-4 and other transcription factors bound to
neighboring or more distal sites, for the complete AMPK-mediated
induction of the promoter.
In summary, we describe the transcriptional activation of the
PGC-1a promoter in response to AMPK activation. Although it
cannot be definitively be ruled out that AICAR may have unknown
effects other than AMPK activation, our study clearly demonstrates
thatthe use ofthisactivatorisassociated with an increaseinAMPKa
phosphorylation in Thr172, and that this phosphorylation coincides
with the associated changes in PGC-1a gene transcription. At least
one important mechanism that may account for this effect is the
enhanced GATA/EBox DNA binding, an effect that is primarily
mediated by USF-1. The activation of the PGC-1a promoter can
also be stimulated by the independent actions of USF-1 and GATA-
4. Thus, we have described potential novel AMPK transcription
factor targets which further contribute to the elucidation of the
mechanisms that underlie the induction of PGC-1a in skeletal
muscle. A complete understanding of the regulation of PGC-1a
expression in skeletal muscle has potential therapeutic value, since
low levels of this coactivator are associated with a disruption of
energy homeostasis [11,46] and the manifestation of diseases such as
insulin resistance and diabetes [12,47].
Materials and Methods
Chemicals and Reagents
5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR)
was purchased from Calbiochem (La Jolla, CA). AICAR was
resuspended in sterile double distilled H20a t5 0m g / m la n ds t o r e da t
220uC. Nitrocellulose membrane and [c-
32P] dATP were obtained
from GE Health Care (Baie D’Urfe ´, Quebec). Restriction enzymes,
phospho-AMPKa (T172; Cat.No.2531) and AMPKa (Cat.No.2532)
antibodies were from New England Biolabs (Mississauga, Ontario).
The pGL3-basic and pGL4.23 (luc2/minP) reporter vectors as well as
the dual luciferase assay system were from Promega (Madison, WI).
Lipofectamine 2000 and SuperscriptII first strand cDNA synthesis kit
was obtained from Invitrogen (Burlington, Ontario). Cell culture
reagents were purchased from Sigma (St. Louis, MO). Synthetic
oligonucleotides and PCR primers were from Sigma Genosys
(Toronto, Ontario). Antibodies against GATA-4 (H-112), and
USF-1 (H-86), c-myc (C-33), SRF (G-20), and MyoD (C-20) were
purchased from Santa Cruz (Santa Cruz, CA). The GAPDH
antibody (ab8245-100) was from Abcam (Cambridge, MA).
Cell culture and treatments
C2C12 muscle cells were cultured as previously described [9].
Briefly, cells were maintained in DMEM containing 10% FBS and
16 Antibiotic/Antimycotic. When cells reached 90% confluence,
they were switched to DMEM containing 5%-heat inactivated horse
serum and 16Antibiotic/Antimycotic and treated for 24 hours with
either vehicle or AICAR (1 mM), to activate AMP kinase [48].
PGC-1a promoter cloning and construction of plasmids
A 2.2 kb fragment of the human PGC-1a promoter was
generated by PCR using genomic DNA isolated from skin
fibroblasts as a template. PCR primers were designed from the
PGC-1a promoter sequence (Gen Bank Accession Number BD
103728; sense: 59-GCT GGT ACC GTG TCC AGT ACC TTG
AGT TTG -39, antisense: 59-ACA CTC ATG CAG GCA ACC
AG-39). The cloned fragment was ligated into the KpnI- and
HindIII- digested sites of the pGL3-basic vector containing the
luciferase reporter gene. This fragment (p 2218) contains 2190
base pairs 59- and 28 base pairs 39 relative to the transcription start
site and served as a template to generate 59-serial deletions of the
promoter. The resulting PCR-amplified fragments containing
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relative to the transcription start site, were ligated into KpnI- and
HindIII- digested sites of the pGL3-basic vector containing the
luciferase reporter gene. These constructs generated plasmids
p 1164, p 851, p 501, and p 191, respectively. The p851DEbox
reporter construct containing a CARTC mutation to prevent
Ebox protein/DNA binding was generated by PCR. The AICAR-
responsive region (ARR) was cloned into the Kpn1- and HindIII-
digested sites of the pGL4.23 promoter reporter vector containing
a minimal promoter. All plasmids were verified by sequencing.
Luciferase reporter assay and transient transfections
Where indicated, C2C12 cells were cultured in 6-well dishes and
transiently transfected with 500 ng of the reporter plasmids, GATA-
4( 2mgo r4mg) and/or USF-1 (2 mgo r4mg) using Lipofectamine
2000, following the manufacturer’s recommendations. The amount
of DNA in each transfection was kept constant by the addition of the
appropriate empty vector (EV) controls. Transfection efficiency was
normalized to Renilla luciferase activity (pRL-CMV; 5 ng/plate).
Following treatments, cell extracts were prepared using 16Passive
Lysis Buffer. Luciferase activities were measured using an EG&G
Berthold (Lumat LB9507) luminometer, according to the manufac-
turer’s instructions. The GATA-4 and USF-1 expression plasmids
have been described elsewhere [49,50].
Nuclear extract preparation and Electrophoretic mobility
assays (EMSA)
Nuclear extracts used in EMSAs were as done previously
described [51]. Briefly, extracts (5-15 mg) were incubated with
20 mg/ml poly(dI-dC), 50 mM PPi and 40,000 CPM of [c-
32P]
dATP end-labeled oligonucleotides containing putative DNA
consensus sequences (in bold) within the 2473 and 2823 bp
region of the hPGC-1a promoter corresponding to the EBox (59-
CTA ACA CTT GTT TTC TGG GAG C-39), SRE (59-GGA
TGT CCA TAT TAG GAC ATC CT-3;), IRS (59-TAC AGC
CTA TTT TGT TGA TTA A -39), GATA/EBox (59-GCA TCA
TGT GAT AAG GCT CCT GC-39), GATAmt in which the
GATA sequence was mutated (mutations are underlined; 59-GCA
TCA TGT GGC AAG GCT CCT GC-39), and EBoxmt in which
the EBox sequence was mutated (mutated are underlined; 59-GCA
TTC TGT GAT AAG GCT CCT GC-39). Samples were run on
native 5% acrylamide gels for 1.5 hours at 250 V. Gels were
subsequently fixed for 15 mins (acetic acid/methanol/water
(10:30:60), dried and imaged using an instant imager (Packard).
Chromatin Immunoprecipitation (ChIP)
ChIP assays were conducted using the ChIP-IT Express Kit
(Active Motif) according to the manufacturer’s instructions. Briefly,
cells in three 150 mm plates per condition were crosslinked with 1%
formaldehyde for 10 mins at room temperature. The reaction was
stopped with the addition of Glycine Stop-Fix solution, and then
washed with ice-cold 16PBS. Cells were pooled, pelleted and then
incubated on ice for 30 mins in 16Lysis Buffer supplemented with
100 mM PMSF and Protease Cocktail Inhibitor Mix. Cells were
then transferred to an ice-cold dounce homogenizer and homoge-
nized on ice with 40 strokes to aid in the release of nuclei. Following
sonication (35 pulses, 20 sec/pulse at 25–30% power) and
centrifugation, 12 mg of sheared chromatin was incubated with
magnetic-coupled Protein G beads, anti-USF1 or IgG (as negative
control) overnight at 4uC. An aliquot of chromatin that was not
incubated with an antibody was used as the input control sample.
Antibody-bound protein/DNA complexes were washed, eluted, and
treatedwithProteinaseKtodigestproteins.Thechromatinwasthen
used in PCR analyses. Primers amplifying the mouse PGC-1a
promoter were: F: 59AGC TGA TCT GAG CAG AGC AG-39 and
R: 59-CTC AAG CTC AGT TTG GGA CT-39, which generated a
543 bp product. PCR products were resolved on 1.8% agarose gels
containing ethidium bromide. Gels were scanned and quantified
with SigmaGel software (Jandel).
Reverse transcription PCR
Total RNA from vehicle- and AICAR-treated C2C12 cells was
isolated using TRIzol reagent, following the manufacturer’s
recommendations. The purity and concentration of total RNA was
determined spectrophotemetrically. Equal amounts (0.5 mg) of total
RNA were reverse transcribed using Superscript II with Oligo-
18(dT) as primer, following the manufacturer’s recommendations.
Sequence-specific primers to amplify PGC-1a (59-GAC CAC AAA
CGA TGA CCC TCC-39 (F) and 59-GCC TCC AAA GTC TCT
CTC AGG-39 (R) and GAPDH 59-TGC TGA GTA TGT CGT
GGA GTC TA-39 (F) and 59-AGT GGG AGT TGC TGT TGA
AGT CG-39 (R) were used, yielding product sizes of 635 bp and
602 bp, respectively [52]. PCR reactions were carried out in a 50 ml
volume containing 2 mlc D N A ,1 0 ml5 6 GoTaqDNA Buffer,
0.2 mM dNTPs, 3 mM MgCl2, and 1 unit of Taq DNA polymerase.
Total RNA samples were also tested without the addition of reverse
transcriptase to verify the absence of genomic DNA contamination.
The conditions for both primer sets included an initial denaturing
step (94uC at 2.5 mins). PGC-1a was then amplified using the
following conditions: denaturation at 94uC for 30 sec, annealing at
69uC for 30 sec, and extension at 72uC for 30 sec for 29 cycles with
an additional 5 minute extension time. GAPDH was amplified using
the following conditions: denaturation at 94uC for 30 sec, annealing
and extension at 72uC for 30 sec for 23 cycles with an additional
5 minute extension time. Optimal cycle number was determined to
obtain a PCR product within the linear range. PCR products were
resolved on 1.8% agarose gels, scanned and quantified with
SigmaGel software (Jandel).
Western Blotting
Totalprotein wasisolated from C2C12cellsasdone previously[9].
Briefly, total protein (20–40 mg) was electrophoresed through SDS-
polyacrylamide gels and transferred onto nitrocellulose membranes.
The membranes were subsequently probed overnight with antibod-
ies directed toward GAPDH (1:20,000), GATA-4 (1:1,000), USF-1
(1:500), phospho-AMPKa (1:400), or AMPKa (1:1,000), washed
365 mins with TBS-Tween20, incubated for 1 hour at room
temperature with the appropriate secondary antibodies conjugated
to horseradish peroxidase, visualized with enhanced chemilumines-
cence, and quantified using SigmaScanPro (Jandel, San Rafael, CA).
Statistics
All data are expressed as means6S.E.M. Where indicated,
Students’ unpaired t-test or 2-way ANOVAs followed by
Bonferroni post-hoc tests, respectively, were used to determine
individual difference between conditions. Results were considered
to be statistically significant if p,0.05 was achieved.
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